SynthesisFrontiers in pharmacology2025
Effects and safety of Salvia miltiorrhiza on the improvement of renal function, inflammatory factors, and vascular endothelium in patients with diabetic kidney disease: a meta-analysis and systematic review.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research trends and potential molecular intersections between diabetic kidney disease and sarcopenia: a 21-year bibliometric and bioinformatics analysis.Frontiers in endocrinology · 2026Review
- Global Research Trends in Traditional Chinese Medicine for Diabetic Kidney Disease: A 20-Year Bibliometric Analysis.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To elucidate the efficacy and safety of Radix et rhizoma Salvia miltiorrhiza (SM) in the treatment of Diabetic Kidney Disease (DKD), and to provide a rationale and scientific reference for the use of SM preparations in the treatment of DKD. This study is the first systematic evaluation and Meta-analysis focusing exclusively on the use of SM as a single agent in the treatment of DKD. Methods: A comprehensive search was conducted in PubMed, Web of Science, Cochrane Library, Elsevier Science Direct, CNKI, Wanfang, and VIP databases, covering the timeframe from the inception of the journals to May 2025. The search was restricted to randomized controlled trials conducted within the past decade that investigated the use of SM/SM preparations as a treatment for DKD. The control group received conventional interventions, while the intervention group received SM/SM preparations. Endnote 20 and Excel were employed for literature management and data organization, and Revman 5.3 and Stata 18 software were used for the analyses. Results: This study involved 21 RCTs with 1970 participants. The results demonstrated that SM preparations led to reductions in serum creatinine (Scr), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER), 24-h urinary total protein (24 h-utp), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and endothelin-1 (ET-1) levels among patients with DKD ( Conclusion: These results indicate that SM preparations could considerably improve renal and vascular endothelial function while simultaneously decreasing harmful inflammatory markers in patients with DKD, which allow it serve as a safe and effective therapeutic option. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42024623452.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.